Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the conclusion of a Phase I clinical study for its OT-202, a tyrosine kinase inhibitor (TKI) being developed to treat dry eye. This marks a significant step in the development of innovative treatments for this common condition.
Study Design and Results
The randomized, double-blind, placebo-controlled study was designed to assess the safety, tolerability, and pharmacokinetics of the Category 1 drug in healthy subjects in China with single or multiple administrations. A total of 30 subjects were enrolled in the study, where OT-202 demonstrated good safety and tolerability characteristics. These results provide a strong foundation for further clinical development.
Mechanism of Action
OT-202 exerts its therapeutic effects by inhibiting the activities of Syk, a key enzyme involved in inflammatory pathways. This mechanism of action positions the drug as a potential anti-inflammatory treatment for dry eye, addressing a significant unmet medical need.-Fineline Info & Tech
